Turnover: 10.2 million EUR (2019)

Country: France

Cellectis is developing the very first allogeneic immunotherapies based on CAR-T cells, inventing the concept of off-the-shelf ingested CAR-T cells ready for use in the treatment of cancer patients. By capitalizing on its 19 years of expertise in genome engineering, its TALEN ® and the pioneering PulseAgile electroporation technology, Cellectis develops innovative product candidates using the power of the immune system to target and eliminate cancer cells.

Financial Data

DUNS: 428859052

Address: 8 RUE DE LA CROIX JARRY , 75013 PARIS 13

Number of employees: Entre 50 et 99 salariés (2018)

Capital: 2 124 456 EUR

Financial Data:

Year Turnover (€) Net Profit (€) Fiscal Year End Fiscal Year Duration
2017 26 326 831 EUR -43 220 689 EUR 31/12/2017 12

Company Managers:

Position First Name Last Name Age Linkedin
Directeur général André Choulika 58
Directeur général délégué David Sourdive 56

Studies mentioning this company